Analogic Corp. is acquiring Ultrasonix Medical Corp., a supplier of ultrasound systems for point-of-care and general imaging applications. Ultrasonix has more than 5,000 systems installed worldwide, and would bring key ultrasound products, technology and sales channels that are complementary to Analogic's ultrasound business.

In what one day may be recognized as a melding of epidemiology and medical imaging, researchers are associating human conditions once viewed as unavoidable or natural consequences of American life as diseases with commonalities that can be seen and measured in the living brain.

Matakina International announced that the Volpara objective breast density measurement software will be used in the European Union (EU) collaborative Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation (ASSURE) research project.

Fujifilm Medical Systems U.S.A. Inc. shared the benefits of its zero footprint mobile application, Synapse Mobility, with visitors to the 2012 meeting of the Radiological Society of North America (RSNA). The application enables access to Fujifilm’s suite of Synapse products from hand-held devices, in addition to Macintosh- or Windows-based PCs. It was one of several Synapse products and solutions demonstrated at the show.

Neurologica purchased by Samsung

Samsung Electronics America, Inc., a subsidiary of Samsung Electronics Co. Ltd, announced its acquisition of NeuroLogica, a leading computed tomography (CT) company headquartered in Danvers, Massachusetts. Established in 2004, NeuroLogica develops cutting-edge medical imaging products and is known for its world-class portable CT scanners, such as BodyTom and CereTom. Terms of the deal were not disclosed.   
MRI, CT Systems Imaging Transparent Pricing Study

In a study designed to see if doctors who are told the exact price of expensive medical tests like magnetic resonance imaging (MRI) in advance would order fewer of them, Johns Hopkins researchers got their answer: No.

Varian Medical Systems has received a U.S. Food and Drug Administration (FDA)- 510(k) clearance for the latest version of its Vitesse real time planning for HDR brachytherapy which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer.

Avreo announced the release of Version 7.4 for preview at HIMSS 2013. Version 7.4 enhancements include voice recognition improvements such as voice command shortcuts, advanced report template management and new voice recognition editor workflow to offer interpreting physicians the option to send voice recognition reports to an editor for final review prior to distribution.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now